Sillajen: 투자판단관련주요경영사항(임상시험계획승인신청) (덱시부프로펜주(WS2405)의 제 1상 임상시험 계획 승인 신청)
AI reading
★★★ Neutral · Material event
덱시부프로펜주 제1상 임상시험 계획 승인 신청
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
For information only. Not investment advice.